Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

An H-2 alloantiserum preserves β-cell function in mice made diabetic by low-dose streptozotocin

Bonnevie-Nielsen, V. and Lernmark, A. LU orcid (1986) In Diabetes 35(5). p.570-573
Abstract

The pancreatic β-cell mass and function in C57BL/KsJ mice is markedly reduced the day after the last injection of five daily injections of a subdiabetogenic, 40 mg/kg, dose of streptozotocin (STZ). In this study, we prepared an H-2 alloantiserum by injecting C57BL/6J mice (H-2b) with spleen lymphocytes from C57BL/KsJ (H-2(d)) mice. The alloantiserum given on five consecutive days, 5 h before each injection of STZ, did not prevent the initial β-cytotoxic effect of STZ detected by perfusion of the pancreas and subsequent morphometric analysis of in situ dithizone-perfused pancreas. However, 12 days after the first injection of STZ, total insulin release in response to D-glucose, total pancreatic insulin, and pancreatic glucagon... (More)

The pancreatic β-cell mass and function in C57BL/KsJ mice is markedly reduced the day after the last injection of five daily injections of a subdiabetogenic, 40 mg/kg, dose of streptozotocin (STZ). In this study, we prepared an H-2 alloantiserum by injecting C57BL/6J mice (H-2b) with spleen lymphocytes from C57BL/KsJ (H-2(d)) mice. The alloantiserum given on five consecutive days, 5 h before each injection of STZ, did not prevent the initial β-cytotoxic effect of STZ detected by perfusion of the pancreas and subsequent morphometric analysis of in situ dithizone-perfused pancreas. However, 12 days after the first injection of STZ, total insulin release in response to D-glucose, total pancreatic insulin, and pancreatic glucagon was greater in the alloantiserum-treated mice compared with controls receiving normal mouse serum. It is concluded that an H-2 alloantiserum may protect the function and amounts of β-cells remaining after the initial five low-dose STZ injections.

(Less)
Please use this url to cite or link to this publication:
author
and
publishing date
type
Contribution to journal
publication status
published
in
Diabetes
volume
35
issue
5
pages
4 pages
publisher
American Diabetes Association Inc.
external identifiers
  • scopus:0022548796
  • pmid:3514332
ISSN
0012-1797
language
English
LU publication?
no
id
4d7e73c0-3d94-4144-8d7c-d0dc018bb705
date added to LUP
2019-09-16 12:34:44
date last changed
2024-03-13 08:20:56
@article{4d7e73c0-3d94-4144-8d7c-d0dc018bb705,
  abstract     = {{<p>The pancreatic β-cell mass and function in C57BL/KsJ mice is markedly reduced the day after the last injection of five daily injections of a subdiabetogenic, 40 mg/kg, dose of streptozotocin (STZ). In this study, we prepared an H-2 alloantiserum by injecting C57BL/6J mice (H-2<sup>b</sup>) with spleen lymphocytes from C57BL/KsJ (H-2(d)) mice. The alloantiserum given on five consecutive days, 5 h before each injection of STZ, did not prevent the initial β-cytotoxic effect of STZ detected by perfusion of the pancreas and subsequent morphometric analysis of in situ dithizone-perfused pancreas. However, 12 days after the first injection of STZ, total insulin release in response to D-glucose, total pancreatic insulin, and pancreatic glucagon was greater in the alloantiserum-treated mice compared with controls receiving normal mouse serum. It is concluded that an H-2 alloantiserum may protect the function and amounts of β-cells remaining after the initial five low-dose STZ injections.</p>}},
  author       = {{Bonnevie-Nielsen, V. and Lernmark, A.}},
  issn         = {{0012-1797}},
  language     = {{eng}},
  month        = {{01}},
  number       = {{5}},
  pages        = {{570--573}},
  publisher    = {{American Diabetes Association Inc.}},
  series       = {{Diabetes}},
  title        = {{An H-2 alloantiserum preserves β-cell function in mice made diabetic by low-dose streptozotocin}},
  volume       = {{35}},
  year         = {{1986}},
}